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Effector CD4+ T cell subsets, whose differentiation is
facilitated by distinct cytokine cues, amplify the cor-
responding type of inflammatory response. Regula-
tory T (Treg) cells integrate environmental cues to
suppress particular types of inflammation. In this
regard, STAT3, a transcription factor essential for
T helper 17 (Th17) cell differentiation, is necessary
for Treg cell-mediated control of Th17 cell responses.
Here, we showed that anti-inflammatory interleukin-
10 (IL-10), and not proinflammatory IL-6 and IL-23
cytokine signaling, endowed Treg cells with the
ability to suppress pathogenic Th17 cell responses.
Ablation of the IL-10 receptor in Treg cells resulted
in selective dysregulation of Th17 cell responses
and colitis similar to that observed in mice harboring
STAT3-deficient Treg cells. Thus, Treg cells limit Th17
cell inflammation by serving as principal amplifiers of
negative regulatory circuits operating in immune
effector cells.INTRODUCTION
Protective immunity against different classes of pathogens is
dependent upon generation of distinct types of immune
responses mediated and coordinated by T helper 1 (Th1), Th2,
and Th17 effector CD4+ T cells. The signals promoting differen-
tiation of naive CD4+ T cells into a particular T helper cell subset
are provided by distinct sets of secreted and membrane bound
cytokines elaborated upon triggering of innate immune sensors
of infection (e.g., Toll-like receptors, inflammasomes, RIG-I,
and MDA5) displayed by antigen-presenting cells (APCs).
Activation of members of the STAT transcription factor family
downstream of corresponding cytokine receptors is critical for566 Immunity 34, 566–578, April 22, 2011 ª2011 Elsevier Inc.generation of the effector CD4+ T cell subsets. For example, acti-
vation of STAT3 downstream of IL-6, IL-23, and IL-21 receptors
is required for efficient generation of highly inflammatory Th17
cells essential for protective immunity against yeast, fungi, and
extracellular bacteria (Adamson et al., 2009; Littman and Ruden-
sky, 2010; Xu and Cao, 2010). Th17 cells specific for self-anti-
gens and, possibly, for commensal microbiota have been also
implicated in autoimmune diseases such as inflammatory bowel
disease, arthritis, and psoriasis (Ahern et al., 2008; McKenzie
et al., 2006). In both immunity to infection and autoimmunity,
effector CD4+ T cells act foremost as critical amplifiers and
‘‘recruiters’’ of the appropriate types of inflammatory immune
responses mediated by cells of both the innate and adaptive
immune systems (Littman and Rudensky, 2010).
In addition to a response mode tailored to protect against
a particular type of pathogen, a successful immune defense
strategy requires intricate negative regulation to restrict host
tissue damage caused by the inflammation. Besides cell-
intrinsic downmodulation of signaling through antigen-specific
and innate receptors, these mechanisms include elaboration of
inhibitory soluble mediators by immune effector cells acting in
both an autocrine and paracrine manner. Among these media-
tors, IL-10, which can be produced by multiple immune cell
types, plays a particularly prominent role in curtailing immune-
mediated inflammation in the context of infection, allergy, and
autoimmunity (Moore et al., 2001; Saraiva and O’Garra, 2010).
The negative regulation afforded by immune effector cells
themselves is complemented by suppression of inflammatory
responses by regulatory T (Treg) cells. These cells, characterized
by the expression of the X chromosome-encoded transcription
factor Foxp3, are vital for preventing autoimmunity and
immune-mediated inflammation elicited by commensal micro-
biota and by pathogens, especially during chronic infection.
Treg cell deficiency resulting from deletion or loss-of-function
mutations of the Foxp3 gene causes a fatal lympho- and myelo-
proliferative inflammatory syndrome characterized by massive
cytokine storm including sharply increased amounts of Th1,
Th2, and Th17 cell cytokines (Fontenot et al., 2003). Likewise,
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IL-10 Signaling in Treg Cellsablation of Treg cells in adult healthy mice leads to augmented
generation of Th1, Th2, and Th17 cells and death within 2 weeks
fromhighly aggressive inflammatory lesions in a variety of organs
(Kim et al., 2007). These observations suggest a possibility that
Treg cells are able to control different types of the immune
response by tailoring their suppressive function to a particular
inflammatory environment. In support of this notion, in Treg cells,
expression of T-bet and IRF-4 (transcription factors involved in
Th1 and Th2 cell differentiation, respectively) facilitates Treg
cell-mediated suppression of the corresponding type of
response (Koch et al., 2009; Zheng et al., 2009). Along the
same lines, Treg cell-specific deletion of STAT3, a transcription
factor necessary for Th17 cell differentiation, results in a fatal
Th17 cell-driven colitis (Chaudhry et al., 2009). In Treg cells, acti-
vated STAT3 and Foxp3 cooperatively regulate a subset of
genes, which probably endows Treg cells with the ability to
suppress Th17 cell-mediated inflammation (Chaudhry et al.,
2009).
STAT3 can be activated downstream of receptors for several
proinflammatory cytokines including IL-6 and IL-23, which serve
as critical inducers of Th17 cell responses, as well as IL-10,
known to restrain Th17 cell-mediated inflammation (Gu et al.,
2008; McGeachy et al., 2007; Yen et al., 2006). These observa-
tions raise a question as to whether the ability of Treg cells to
suppress Th17 cell-mediated inflammation is imparted upon
sensing proinflammatory (IL-6 and IL-23) or anti-inflammatory
(IL-10) cues. The former scenario would suggest that Treg cell-
mediated suppression represents negative feedback regulation
induced by an inflammatory environment. In contrast, the latter
scenario implies that Treg cells amplify negative regulators
elicited by immune effector cells. Here, we demonstrate that
IL-10R, but not IL-6R or IL-23R, was required for Treg cell-medi-
ated suppression of spontaneous Th17 cell-driven colitis. Thus,
in analogy with amplification of effector immune responses by
distinct types of Th cells, Treg cells act as amplifiers of negative
regulatory circuits of immune effector cells to restrain Th17 cell-
mediated inflammation.
RESULTS
IL-10 Elicits Potent STAT3 Phosphorylation in Treg Cells
STAT3 activation elicited by IL-6, IL-23, and IL-21 is indispensable
for differentiation of activated T cells into Th17 effector cells. In
addition to these proinflammatory cytokines, STAT3 phosphoryla-
tion can be induced by the anti-inflammatory cytokine IL-10,
known to oppose Th17 cell responses (O’Shea and Murray,
2008). Our recent studies showed that in suppressive Treg cells,
STAT3 plays an essential role for their ability to suppress patho-
genic Th17cell responses (Chaudhryet al., 2009). Thus,wesought
to explore whether pro- or anti-inflammatory cytokine signaling
confers upon Treg cells the ability to restrain Th17 cell-dependent
inflammation. Because thresholds and consequences of STAT3
activation elicited by different cytokines differ between various
cell types, we first assessed STAT3 phosphorylation in response
to titrated amounts of IL-6 and IL-10 in conventional naive CD4+
Foxp3 T cells and Treg cells. Amounts of phosphorylated
STAT3 (pSTAT3; Y705) were determined via flow cytometric or
immunoblot analyses. We found that stimulation of naive CD4+
and CD8+ T cells with IL-6 induced markedly higher pSTAT3 ascompared to IL-10. In contrast, IL-10 was a more potent inducer
of STAT3 phosphorylation in Treg cells as compared to naive
T cells (Figures 1A–1C). The total STAT3 amounts were not
changed upon cytokine treatment. These findings indicate that
the proinflammatory cytokine IL-6 is more effective in inducing
STAT3 activation in naive T cells, whereas in Treg cells, the anti-
inflammatory cytokine IL-10 triggers more efficient STAT3 phos-
phorylation. Furthermore, basal amounts of pSTAT3 in unstimu-
lated T cells and Treg cells after IL-23 treatment were not different
(datanot shown).Several factorscanaccount for thesedifferences
including varying surface expression of the corresponding cyto-
kine receptors and altered expressionof either positive or negative
regulators of STAT3 activation. Regardless of the mechanism
underlying the contrasting pattern of Treg and naive T cell respon-
siveness to IL-6and IL-10, these results suggest that Tregcells are
poised to sense IL-10 and that IL-10R on Treg cells plays a pivotal
role in their function.
Impaired STAT3 Phosphorylation in IL-10R- but Not
IL-6R-Deficient Treg Cells
To directly explore this possibility, we induced Treg cell-specific
ablation of IL-10R and IL-6R by breedingmice harboring a condi-
tional allele encoding IL-10Ra (Il10rafl) or IL-6Ra (Il6rafl) chain
with Foxp3Cre mice (Pils et al., 2010; Wunderlich et al., 2010;
Rubtsov et al., 2008). Foxp3CreIl10rafl/fl and Foxp3CreIl6rafl/fl
mice were born at an expected Mendelian ratio and efficiency
of deletion was confirmed by quantitative PCR (Figure S1 avail-
able online). We then tested the assumption that IL-10R plays
a nonredundant role in STAT3 activation in Treg cells by
analyzing pSTAT3 in MACS-purified CD4+CD25+ Treg cells iso-
lated from spleens and lymph nodes of healthy 3- to 4-week-old
Foxp3CreIl10rafl/fl or littermate control Foxp3CreIl10rawt/wt mice.
IL-10R-deficient Treg cells showed reduced pSTAT3 as
compared to littermate controls. In contrast, no differences in
pSTAT3 amounts were observed in IL-6R-deficient as compared
to IL-6R-sufficient Treg cells (Figure 1D). These results indicated
that IL-10R signaling is an important contributor to STAT3 activa-
tion in Treg cells in accordance with the in vitro analysis of STAT3
phosphorylation in Treg cells.
Mice Harboring IL-10R-Deficient Treg Cells Developed
Severe Immune-Mediated Colitis
Although Foxp3CreIl10rafl/fl mice appeared healthy up to 8–10
weeks of age, these mice developed clinical symptoms of
immune-mediated colitis later in life. At 13–14 weeks of age,
they exhibited failure to thrive, splenomegaly, and pronounced
enlargement of mesenteric lymph nodes (Figure 2A). Despite
unchanged or even somewhat reduced numbers of T cells in
the lymph nodes and spleen, we observed a marked increase
in activated CD44hiCD62LloCD4+ T cells in these mice as
compared to littermate controls (Figures 2B–2D). Moreover,
these mice developed weight loss, rectal prolapse, and colon
thickening and succumbed to the disease by 18–20 weeks of
age (Figure 2G). These clinical manifestations are hallmarks of
inflammatory bowel disease (IBD), which was confirmed by
histological examination of the intestinal tissues (Figure 2H). In
particular, the colon of the affected mice exhibited marked
thickening of the mucosa with dense lymphoid and lesser
neutrophilic infiltration, crypt loss and abscessation, regions ofImmunity 34, 566–578, April 22, 2011 ª2011 Elsevier Inc. 567
1 10 100 1000
0.00
0.25
0.50
B cells
CD8
IL-10 (ng/ml)
1 10 100 1000
0.0
0.2
0.4
0.6
0.8
IL-6 (ng/ml)
N
or
m
al
iz
ed
 p
ST
AT
3 
(M
FI 
pS
TA
T3
/M
FI 
ST
AT
3)
0 10 2 103 104 105
0
20
40
60
80
100
0 10 2 103 104 105
0
20
40
60
80
100
%
 o
f m
ax
pSTAT3
B
C
pSTAT3
STAT3
pSTAT3
STAT3
IL-6 IL-10- IL-6 IL-10-
CD4 Foxp3-+ CD4 Foxp3++
IL-6
IL-10
A
D
pSTAT3
STAT3
F
o
x
p
3
 
 
 
I
l1
0
r
a
w
t
l/
w
t
f
l/
f
l
f
l/
f
l
C
r
e
F
o
x
p
3
 
 
 
I
l1
0
r
a
C
r
e
F
o
x
p
3
 
 
I
l6
r
a
W
t
f
l/
f
l
F
o
x
p
3
 
 
 
I
l6
r
a
C
r
e
CD4 Foxp3++
CD4 Foxp3-+
CD8
CD4 Foxp3++
CD4 Foxp3-+
pSTAT3/STAT3: 1.00  0.53 1.00  0.95
pS
TA
T3
/S
TA
T3
 ra
tio
0.0
0.5
1.0
1.5
F
o
x
p
3
 
 
 
I
l1
0
r
a
w
t
l/
w
t
f
l/
f
l
f
l/
f
l
C
r
e
F
o
x
p
3
 
 
 
I
l1
0
r
a
C
r
e
F
o
x
p
3
 
 
I
l6
r
a
W
t
f
l/
f
l
F
o
x
p
3
 
 
 
I
l6
r
a
C
r
e
pSTAT3/STAT3:  1.0   3.8   8.7  10.4  3.6   6.7  7.3 pSTAT3/STAT3:  1.0    1.2   1.9   2.2   2.0   2.9  3.5
Y705
∗∗
Figure 1. IL-10 Induces Robust STAT3 Phosphorylation in Treg Cells
(A) Flow cytometric analysis of pSTAT3 (Y705) amounts after treatment of splenic CD4+Foxp3 T cells, CD4+Foxp3+ Treg cells, and CD8 T cells with recombinant
IL-6 (16 ng/ml) or IL-10 (100 ng/ml) for 15 min.
(B and C) Analysis of pSTAT3 levels by either flow cytometry (B) or immunoblotting (C) after stimulation of indicated cells with titrating doses (3, 10, and 15 ng/ml
for IL-6; 50, 150, and 300 ng/ml for IL-10) of recombinant IL-6 or IL-10.
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IL-10 Signaling in Treg Cellsglandular hyperplasia with irregular gland formation, and
increased mitotic figures. In the most severely affected mice,
the inflammation was transmural extending to the attached
mesentery (Figure 2I). Unlike colitic Foxp3CreIl10rafl/fl mice,
where essentially all Treg cells lacked IL-10R, heterozygote
female Foxp3Cre/wtIl10rafl/fl mice, harboring both IL-10R-suffi-
cient and -deficient Treg cells, remained disease-free (Figure S2).
The heightened activation of CD4+ T cells in the presence of
IL-10R-deficient Treg cells was not due to diminished numbers,
but rather the frequency and absolute numbers of Treg cells
were increased in Foxp3CreIl10rafl/fl mice (Figures 2E and 2F).
Furthermore, the IL-10R-sufficient and -deficient Treg cells ex-
pressed similar amounts of Foxp3 (Figure 2E), excluding dimin-
ished Foxp3 expression as an explanation for the pathology in
Foxp3CreIl10rafl/fl mice.
IL-10R Deficiency Does Not Impair Stability of Foxp3
Expression in Treg Cells
A recent study suggested that upon adoptive transfer of naive
CD4+ T cells and Treg cells into lymphopenic hosts, innate
immune cell production of IL-10 in the recipients is required to
maintain Foxp3 expression (Murai et al., 2009). In this study,
Treg cells lacking IL-10R lost Foxp3 expression and thus their
suppressor function under inflammatory conditions and, hence,
severe colitis commenced in lymphopenic hosts. Because
Foxp3CreIl10rafl/fl mice develop similar pathology, it was plausible
that the phenotype observed in our studies was due to a loss of
Foxp3 expression in the absence of IL-10R. Although flow cyto-
metric analysis did not reveal any difference in Foxp3 amounts
on per cell basis between Foxp3CreIl10rafl/fl mice and control
littermates (Figure 2E), it was still possible that loss of Foxp3
expression by some IL-10R-deficient Treg cells was masked by
proliferation of newly generated Treg cells. To address this impor-
tant caveat, we employed inducible ablation of the Il10rafl allele in
Treg cells by using Cre-ERt2 recombinase and assessed Foxp3
expression (Rubtsov et al., 2010). For these experiments, we
crossed the Il10rafl mice to knockin Foxp3Cre-ERt2 mice that
express a triple fusion protein of the enhanced green fluorescent
protein (eGFP) with Cre recombinase and mutated human
estrogen receptor ligand-binding domain (ERt2) under control of
the Foxp3 gene. These mice were equipped with a Cre-mediated
recombination reporter allele containing a loxP site-flankedSTOP
cassette followed by a DNA sequence encoding yellow fluores-
cent protein (YFP) knocked into the ubiquitously expressed
ROSA26 locus (R26Y). Treatment of these mice with tamoxifen
induced Cre-ERt2-mediated IL-10R ablation and YFP tagging
upon excision of the STOP cassette. Genetic labeling of Foxp3-
expressing cells with YFP via inducible recombination avoids
the continuous incorporation into the labeled population of cells
that transiently upregulate Foxp3 and affords assessment of
Foxp3 stability in differentiated Treg cells. Thus, Foxp3Cre-ERt2
Il10rafl/flR26Y and littermate control mice were administered
tamoxifen and analyzed 3 and 12 weeks later for Foxp3 expres-
sion in YFP+CD4+ T cells. We found that IL-10R ablation did not
affect Foxp3 expression within splenic and lymph node cells(D) Immunoblot detection of pSTAT3 and STAT3 in Treg cells isolated from IL-10
Data are representative of four independent experiments. Error bars represent mand that essentially all YFP+ tagged cells expressed unaltered
amounts of Foxp3 at both time points (Figure 3A). These results
were also confirmed by intracellular staining for Foxp3 and flow
cytometric analysis of FACS-purified YFP+ cells at both time
points (Figure 3B).Moreover, analysis of Foxp3mRNAexpression
in the sorted YFP+ cells by quantitative PCR (qPCR) also did
not detect a measurable loss of Foxp3 in IL-10R-ablated Treg
cells.Asexpected, expressionof IL-10RmRNAweresubstantially
lower in YFP+ Treg cells isolated from Foxp3Cre-ERt2Il10rafl/flR26Y
mice as compared to the control animals (Figure 3C). Further
characterization of the YFP-tagged IL-10R-deficient Treg cells
did not reveal changes in expression of Th1, Th2, and Th17 cell-
specific transcription factors and corresponding cytokines
(Figure S3). These findings effectively exclude a loss of Foxp3
expression as an explanation for the observed inability of
IL-10R-deficient Treg cells to suppress intestinal inflammation.
Unimpaired Function of IL-6R- and IL-23R-Deficient
Treg Cells In Vivo
In contrast to immunosuppressive effects of IL-10, IL-6 signaling
on T cells has been suggested to be critical for mediating as well
as sustaining enteric inflammation (Fasnacht et al., 2009). To
identify whether IL-6 signaling plays a similar role in Treg cells,
we examined Foxp3CreIl6rafl/fl mice. IL-6R ablation in Treg cells
did not result in noticeable changes in cytokine production or
activation status and numbers of T cells and other immune cell
types including granulocytes, macrophages, B cells, NK cells,
and dendritic cells (Figure S4; data not shown). Accordingly,
phenotype of Treg cells in Foxp3CreIl6rafl/fl mice was indistin-
guishable from that in littermate controls and both groups of
mice remained healthy.
To assess potential role for IL-23R in Treg cell function, we
generated mixed bone marrow (BM) chimeras by transferring
T cell-depleted BM cells from IL-23R-deficient (Il23r/) or -suffi-
cient Ly5.2 B6micemixedwith BMcells from Ly5.1+Foxp3mice
into lethally irradiated (900 rads) Rag2/ recipients. In these
experimental chimeric mice, all Treg cells lacked IL-23R expres-
sion. Irradiated Rag2/ recipients reconstituted with Foxp3
BM cells alone, which served as a positive control for immune-
mediated lesions, died within 5–6 weeks after BM transfer (data
not shown). In contrast, IL-23R-deficient Treg cells appeared fully
functional and (Il23r/ + Foxp3)/Rag2/ BM chimeras were
healthy and devoid of measurable signs of T cell activation, lym-
phoproliferation, and immune-mediated pathology (Figure S5).
Thus, in contrast to IL-10R ablation, IL-6R or IL-23R deficiency
in Treg cells did not have noticeable effect on their function.
Increased IL-17 Production in the Presence
of IL-10R-Deficient Treg Cells
Examination of the surface phenotype of Treg cells from
Foxp3CreIl10rafl/fl mice indicated a heightened activation of Treg
cells in these mice (Figure 4A). Although the frequency of prolif-
erating Ki67+ cells within IL-10R-deficient Treg cell population
was unchanged, expression of various characteristic Treg cell
surface markers including those associated with theirR- or IL-6R-deficient and -sufficient mice.
ean ± SE (**p < 0.001).
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Figure 3. IL-10R Ablation Does Not Affect Foxp3 Expression and Treg Cell Lineage Stability
(A) Flow cytometric analysis of Foxp3 and YFP expression in splenic CD4+ T cells in Foxp3CreIl10rafl/flR26Y and control littermate mice.
(B) Expression of Foxp3 in flow cytometry-sorted CD4+YFP+ T cells from indicated mice.
(C) Quantitative PCR (qPCR) analysis of Foxp3 and IL-10Ra expression in flow cytometry-sorted CD4+YFP+ T cells. The gray bar represents CD4+YFP T cells.
The results represent the mean ± SD of relative expression values for the indicated genes relative to hypoxanthine-guanine phosphoribosyl transferase.
Data are representative of three independent experiments.
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IL-10 Signaling in Treg Cellssuppressor function (e.g., CTLA-4) were markedly augmented in
Foxp3CreIl10rafl/fl mice in comparison to littermate control mice.
The observed Treg cell activation was due to severe colonic
inflammation because IL-10R-deficient Treg cells did not exhibit
signs of activation in the presence of IL-10R-sufficient counter-
parts in healthy heterozygote female Foxp3Cre/wtIl10rafl/fl mice
(Figure S2). Thus, IL-10R-deficient Treg cells, like STAT3-defi-Figure 2. Treg Cell-Specific IL-10R Deletion Results in Severe Intestin
(A and B) Spleen and lymph node cellularity (A) and frequencies of CD4 and CD8 T
(C and D) Frequencies of activated T cells.
(E and F) Levels of Foxp3 in gated CD4+ T cells and frequencies of CD4+Foxp3+
(G) Body weights of Foxp3CreIl10rafl/fl mice (n = 7).
(H) IBD scores derived from evaluation of colon and cecum from 14- to 16-week
(I) Representative H&E-stained sections of large bowel at the level of the ileoceca
with expanded irregular, hyperplastic crypts, glandular loss, and fibrosis with m
(n = 7).
Error bars represent mean ± SE.cient Treg cells, fail to restrain colitis probably because of
impaired suppressor function.
Recent work has demonstrated that inflammatory Th1 and
Th17 cell responses can facilitate both colitis development and
progression (Brand, 2009). Therefore, we assessed T cell
production of different effector cytokines in Foxp3CreIl10rafl/fl
mice. We observed elevated production of Th17 cell-associatedal Inflammation
cells (B) in Foxp3CreIl10rafl/wt and Foxp3CreIl10rafl/fl mice (**p < 0.001; *p < 0.01).
T cells.
-old Foxp3CreIl10rafl/wt and Foxp3CreIl10rafl/fl mice (n = 4/group).
l-colic junction from Foxp3CreIl10rafl/wt and Foxp3CreIl10rafl/fl mice. M, mucosa
ultifocal transmural inflammation (arrow); L, lumen. Original magnification, 53
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IL-10 Signaling in Treg Cellscytokines, IL-17 and IL-22, by CD4+Foxp3 T cells in the pres-
ence of IL-10R-deficient Treg cells (Figures 4B and 4C). In
contrast, production of Th1 and Th2 cell-associated cytokines
IFN-g, IL-4, and IL-5 was comparable in Foxp3CreIl10rafl/fl and
littermate control mice. Production of other cytokines such as
IL-2 was also unaffected (Figures 4B and 4C). Notably, IL-10R-
deficient Foxp3+ Treg cells did not produce any of these cyto-
kines (Figure 4B). Thus, IL-10R-deficient Treg cells were capable
of keeping Th1 and Th2 cell responses in check.
IL-10R-Deficient Treg Cells Fail to Suppress Th17 Cell
Responses In Vivo
These results were consistent with the idea that only a distinct
aspect of the suppressor program was impaired in IL-10R-defi-
cient Treg cells, whereas their general suppressive capacity
was intact. This notion was supported by unimpeded ability of
IL-10R-deficient Treg cells to suppress proliferative responses
of naive T cells in vitro (Figure 5A). To examine suppressor func-
tion in vivo, we cotransferred flow cytometry-purified IL-10R-
deficient or -sufficient Ly5.2+ Treg cells and effector Ly5.1+
CD4 T cells from Foxp3 mice into Rag2/ recipients. Prior to
transfer, the effector CD4+ T cell population was heavily skewed
toward Th1 cells, but also contained Th2 and Th17 polarized
cells (Figure 5B). Effector Foxp3 T cells transferred alone into
Rag2/ recipients induced fatal systemic multiorgan autoim-
mune syndrome associated with lymphoproliferation and
increased Th1, Th2, and Th17 cell cytokine production, similar
to that observed in unmanipulated Foxp3 mice. Cotransfer of
IL-10R-deficient Treg cells and Foxp3 effector T cells resulted
only in dysregulated Th17 cell responses as evidenced by
increased frequencies and absolute numbers of IL-17-producing
Ly5.1+ Foxp3CD4+ T cells in recipient mice (Figure 5C) and
a colitis similar in severity to that seen in Foxp3CreIl10rafl/fl mice
(Figure 5D). Despite failure to suppress Th17 cell-mediated
inflammation, IL-10R-deficient Treg cells were able to restrain
lymphoproliferation as well as Th1 and Th2 cell responses (Fig-
ure 5C). In contrast, all autoimmune and clinical IBD manifesta-
tions were abrogated upon cotransfer of IL-10R-sufficient Treg
cells with only mild subclinical and nonfatal colitis noted histo-
logically (Figure 5D). Thus, these results suggest that IL-10R-
deficient Treg cells are selectively impaired in their ability to
control inflammatory Th17 cell responses and that this impair-
ment leads to fatal colitis.
IL-10R Signaling Facilitates IL-10 Production
by Treg Cells
Although Treg cells employ multiple mechanisms of suppres-
sion, IL-10 produced by Treg cells plays an important role in pre-
venting colonic inflammation. Mice with Treg cell-specific abla-
tion of IL-10 develop spontaneous colitis (Rubtsov et al., 2008).
Thus, it was plausible that IL-10 produced by immune effector
cells elicited STAT3 phosphorylation in Treg cells, which in turn
induced IL-10 production in these cells as well as other media-Figure 4. Increased Treg Cell Activation and Selective Dysregulation o
(A) Flow cytometric analysis of Treg cell activation markers and putative effect
littermate mice.
(B and C) Flow cytometric analysis of cytokine production by splenic CD4+Fo
ionomycin treatment for 4–6 hr (**p < 0.001; *p < 0.01).tors of suppression. STAT3 has recently been shown to directly
bind to a diverse array of targets (Durant et al., 2010). Thus, we
examined STAT3 binding to regulatory elements of the Il10
gene in Treg cells. Indeed, we found that STAT3 binds at the
Il10 locus in Treg cells (Figure 6A). To test whether IL-10R defi-
ciency in Treg cells impairs their ability to produce IL-10, we
examined IL-10 expression at themRNA level in IL-10R-deficient
and -sufficient Treg cells via qPCR. These experiments showed
significantly diminished production of IL-10 by IL-10R-deficient
Treg cells (Figure 6B). Thus, IL-10R signaling in Treg cells leads
to STAT3-dependent expression of IL-10.
In aggregate, our studies implicate sensing of anti-inflamma-
tory cytokine IL-10, but not proinflammatory IL-6 and IL-23, by
Treg cells as an essential facilitator of their suppressor function.
IL-10 produced by diverse immune effector cells induces activa-
tion of STAT3 in Treg cells and thereby facilitates their ability to
suppress Th17 cell responses, which includes IL-10 production
by Treg cells. These results suggest that Treg cells suppress
Th17 cell-mediated inflammation by acting as amplifiers of
negative regulatory mechanisms elaborated by immune effector
cells.
DISCUSSION
IL-17- and IL-22-producing Th17 cells mediate protection
against mycobacterial, fungal, and bacterial infections. Under
physiologic conditions, Th17 cells are found predominantly in
the small and large intestine and associated lymphoid tissues
where they facilitate production of antimicrobial peptides,
enforce integrity of the epithelial barrier, and recruit and activate
granulocytes and macrophages to restrain pathogenic bacteria
(Weaver et al., 2007). Recent studies demonstrated a critical
role of certain components of commensal flora in induction of
Th17 cell responses. In germ-free (GF) mice devoid of
commensal flora, Th17 cells are essentially undetectable but
are prominently present upon colonization of GF mice with
a single commensal microorganism, segmented filamentous
bacterium (Ivanov et al., 2009). Th17 cells play a prominent
role not only in resistance against intestinal pathogens such as
Shigella or Citrobacter (Ouyang et al., 2008), but also in autoim-
mune and inflammatory disorders in the gastrointestinal tract
including Crohn’s disease and ulcerative colitis (Ahern et al.,
2008). The preferential generation of Th17 cells in the small
and large intestine-associated lymphoid tissues and draining
lymph nodes is due to high expression of factors supporting
Th17 cell differentiation. These factors include IL-1, TGF-b, and
STAT3-signaling inflammatory cytokines IL-6, IL-21, and IL-23
(Korn et al., 2009). A complete block of Th17 cell differentiation
in the absence of STAT3 illustrates a critical role for the latter
three cytokines (Mathur et al., 2007; Yang et al., 2007).
Intestinal homeostasis requires restraint of highly inflammatory
Th17 cells by a variety of cell-intrinsic and -extrinsic negative
regulatory mechanisms. Among mechanisms limiting Th17 cellf Th17 Cell Responses in Foxp3CreIl10rafl/fl Mice
or molecules on splenic CD4+Foxp3+ T cells in Foxp3CreIl10rafl/fl and control
xp3 T cells in Foxp3CreIl10rafl/wt and Foxp3CreIl10rafl/fl mice after PMA and
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Figure 5. IL-10R-Deficient Treg Cells Efficiently Control In Vitro T Cell Proliferation but Fail to Suppress Th17 Cell Differentiation and Colitis
(A) IL-10R-deficient and -sufficient Treg cell-mediated suppression of effector T cell (Teff) proliferative responses in vitro.
(B) Frequencies of Th1, Th2, and Th17 skewed cells among the transferred T cell population isolated from the Foxp3 mice.
(C) Frequencies of splenic Treg cells, CD4+IL-17+Foxp3 T cells, CD4+IFN-g+Foxp3 T cells, and CD4+IL-4+Foxp3 T cells within the indicated donor-derived
population 5–6 weeks after cotransfer of either Foxp3CreIl10rafl/wt or Foxp3CreIl10rafl/fl Treg cells with Foxp3CD4+ T cells into Rag2/ recipients.
(D) Representative H&E-stained sections of colon collected from recipient mice 5–6 week after adoptive T cell transfer (original magnification, 103). M, mucosa;
E, submucosal edema; *, dilated lymphatics; and L, lumen.
Error bars represent mean ± SE.
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Figure 6. IL-10R Signaling Is Required for IL-10 Expression by Treg
Cells
(A) qPCR analysis of STAT3-bound chromatin isolated from wild-type Treg
cells via primers corresponding to the indicated genes. House-keeping gene
Gmpr was used as a specificity control while IgG-immunoprecipitated chro-
matin was used as a negative control.
(B) qPCR analysis of relative expression of indicated genes in Treg cells iso-
lated from either Foxp3CreIl10rafl/wt or Foxp3CreIl10rafl/fl mice. The results
represent the mean ± SD of relative expression values for the indicated genes
relative to hypoxanthine-guanine phosphoribosyl transferase.
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a prominent role (Gu et al., 2008; Li and Flavell, 2008; McGeachy
et al., 2007). IL-10 is a powerful negative regulator of the immune-
mediated inflammation with a broad range of target cell types,
primarily of hematopoietic origin (Jankovic et al., 2010). IL-10
has been implicated in limiting inflammation at environmental
interfaces, in particular, in the gut and lung mucosa (Groux and
Cottrez, 2003; Sun et al., 2009). Germline IL-10 deficiency in
mice or inability of T cells to produce IL-10 leads to immune-
mediated colitis (Roers et al., 2004) that is completely dependent
on enteric microflora (Stehr et al., 2009), defining a major tissue-
protective role for IL-10. Not surprisingly, impaired IL-10
signaling has also been implicated in the pathogenesis of IBD,
and recently mutations in the IL-10R genes have been described
in twounrelated familieswith aheritable andpoorly treatable form
of Crohn’s disease (Glocker et al., 2009).
Multiple immune effector cells, including T cells, B cells,
macrophages, dendritic cells, NK cells, neutrophils, eosinophils,
and mast cells, express IL-10 (Saraiva and O’Garra, 2010). In
a naive mouse, B cells have been reported to constitute a domi-
nant source of IL-10 in several lymphoid tissues, and B cell-
derived IL-10 plays a nonredundant role in restraining T cell
responses (Madan et al., 2009). Unlike several other cell types
where IL-10 plays an immunosuppressive function, IL-10 on B
cells acts to prevent apoptosis and enhances proliferation,
differentiation, and MHC II expression in addition to playing
a role in regulation of Ig class switching (Sabat et al., 2010).
The differential activation of STAT3 observed in B cells upon
IL-10 as opposed to IL-6 stimulation probably reflects the crucial
role of IL-10 in B cell function.
Within the T cell subset, activated CD8+ T cells and all three
main effector CD4+ T cell types (Th1, Th17, and Th2 cells) are
capable of secreting IL-10 (Li and Flavell, 2008). Thus, IL-10
production represents an essential negative feedback mecha-
nism elaborated by immune effector cells to limit their activation.In addition to immune effector T cells, suppressive Foxp3 Tr1
and Foxp3+ Treg cells produce IL-10 in the small and large intes-
tine. Recently, we demonstrated that expression of STAT3 in
Treg cells is a prerequisite for their ability to suppress Th17 cell
responses and that ablation of STAT3 in Treg cells results in fatal
Th17 cell-mediated colitis (Chaudhry et al., 2009). Because
STAT3 is required both for elaboration of inflammatory Th17
cell responses and for their suppression by Treg cells, two
models of Treg cell-mediated control of Th17 cell inflammatory
responses can be considered. First, Treg cells directly sense
the inflammatory environment favoring Th17 cell differentiation,
i.e., high amounts of IL-6 and IL-23, which activate STAT3 and
thereby enable Treg cell-mediated suppression of Th17 cell-
dependent inflammation. Alternatively, Treg cells respond to
the anti-inflammatory mediator IL-10 produced by the immune
effector cells. According to this scenario, Treg cells act as ampli-
fiers of the negative regulatory mechanisms elaborated by
immune effector cells in analogy to the aforementioned amplifi-
cation of immune responses by effector T cell subsets. Our
finding that IL-10R signaling in Treg cells was necessary for their
suppression of Th17 cell responses, whereas IL-6R or IL-23R
was dispensable, strongly argues in favor of the latter possibility.
In addition, this finding suggests that the essential role for STAT3
in Treg cells for suppression of Th17 cell inflammation is depen-
dent upon its phosphorylation downstreamof cytokine receptors
and subsequent changes in gene expression.
Colitis observed in Foxp3CreIl10rafl/fl mice was similar to that
observed in mice harboring STAT3-deficient Treg cells, suggest-
ing that IL-10 is the predominant activator of STAT3 signaling in
Treg cells. Like STAT3-deficient Treg cells, IL-10R-deficient
Treg cells also fail to suppress Th17 cell responses, whereas no
increases in Th1 or Th2 cell cytokines were noted. Nevertheless,
clinical colitis progression in the presence of IL-10R-deficient
Tregcellswasslower than that in thepresenceofSTAT3-deficient
Treg cells, implying that an additional STAT3 signaling cytokine(s)
can contribute to some extent to STAT3 activation in Treg cells.
Recent work has suggested that Treg cells may lose Foxp3
expression in inflammatory settings and these ‘‘ex-Treg’’ cells
can contribute to pathology (Murai et al., 2010; Zhou et al.,
2009). In particular, IL-10 signaling was shown to be necessary
for Treg cell stability in an experimental colitismodel. A prominent
loss of Foxp3 was observed upon transfer of purified Il10rb/
Treg cells togetherwith naiveCD4+CD45RBhi T cells into lympho-
penic recipients (Murai et al., 2009). However, we found similar
Foxp3 protein expression in IL-10R-deficient and -sufficient
Treg cells and increased numbers of Foxp3+ cells were present
in Foxp3CreIl10rafl/fl mice. Furthermore, we failed to detect loss
of Foxp3 expression upon cotransfer of effector Foxp3 cells
and IL-10R-deficient Treg cells into lymphopenic recipients.
Finally, we did not observe detectable loss of Foxp3 expression
upon inducible deletion of IL-10R in Treg cells combined with
the cell fate mapping approach via Foxp3Cre-ERt2 and R26Y
recombination reporter allele (Rubtsov et al., 2010). These results
indicate that despite loss of IL-10 signaling, Treg cells remain
stable and that potential downregulation of Foxp3 cannot explain
the inflammatory colitis observed with Treg cell-specific deletion
of IL-10R. One possible explanation for discrepant results is
that few contaminating Foxp3 cells can rapidly expand in lym-
phopenic settings (Komatsu et al., 2009) and that this expansionImmunity 34, 566–578, April 22, 2011 ª2011 Elsevier Inc. 575
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signaling. Furthermore, these incongruent results can also be
potentially dependent on whether Il10ra or Il10rb was utilized to
inactivate IL-10 signaling. Whereas IL-10Ra, required for ligand
binding, is unique to the IL-10R complex, IL-10Rb, essential to
mediate downstream signaling, is shared between several
members of the class II cytokine receptors such as IL-22R and
IFN-lR familymembers (Pestkaet al., 2004). Although theexpres-
sion and function of these receptors on Treg cells have not been
characterized, it remains possible that functions of IL-10Rb unre-
lated to IL-10 signaling can account for this discordance.
Although Treg cell-mediated suppression is not fully under-
stood in mechanistic terms, various studies indicate that Treg
cells utilizemultiplemeans to accomplish suppressionof different
inflammatory responses (Shevach, 2009; Vignali et al., 2008). Our
observation that phosphorylated STAT3 binds to regulatory
elements of the Il10 gene in Treg cells and that IL-10R deficiency
in these cells is associated with drastically reduced IL-10 expres-
sion is indicative of a feed-forward IL-10 loop operating in Treg
cells, i.e., IL-10 produced by variety of cellular sources augments
its own production by Treg cells. Importantly, ablation of IL-10 in
Treg cells leads to spontaneous colitis albeit less severe than that
in Foxp3CreStat3fl/fl or Foxp3CreIl10rafl/fl mice (Rubtsov et al.,
2008). Furthermore, impaired IL-10 signaling in effector T cells
results in augmented Th17 cell but not Th1 cell responses, and
Treg cells can restrain these Th17 cell responses in an IL-10-
dependent manner (Huber et al., 2011). These observations
corroborate our findings that reduced IL-10 production by
IL-10R-deficient Treg cells is likely to affect Th17 but not other
T cell responses.
Our studies indicate that Treg cell-mediated suppression of
Th17 cell-driven pathology is facilitated by activation of STAT3
downstream of IL-10R engagement by IL-10. Subsequent induc-
tion of a STAT3-dependent Th17 cell-suppression program
including IL-10 production by Treg cells can then result in damp-
ening of this Th17 cell response. However, it is also possible that
Treg cells can act on effector T cells to induce IL-10 expression
(Kearley et al., 2005). In either scenario, we suggest that Treg
cells can act as amplifiers of negative regulatory mechanisms,
such as IL-10, that are initially elaborated by immune effector
cells upon their activation. This is in analogy with amplification
of a particular type of innate and adaptive immune responses
by a given effector CD4+ T cell type.
EXPERIMENTAL PROCEDURES
Animals
Foxp3, Foxp3Cre, Foxp3Cre-ERt2, Rosa26YFP, Il6rafl, and Il10rafl mice have been
previouslydescribed (Fontenot et al., 2003;Pils et al., 2010;Rubtsovet al., 2008,
2010;Wunderlich et al., 2010). IL-23R-deficientmicewere kindly provided by V.
Kuchroo (Harvard Medical School). C57BL/6J were purchased from the Jack-
son Laboratories (Bar Harbor, ME). All the mice were bred and housed in the
specific-pathogen-free animal facility at the Memorial Sloan-Kettering Cancer
Center and used in accordancewith institutional guidelines. Tamoxifen (Sigma)
was dissolved in olive oil (Fluka) to a final concentration of 40 mg/ml. Mice
received threedosesof tamoxifen (8mgeach) at days0, 1, and3byoral gavage.
Reagents, Flow Cytometry, and Cell Isolation
Fluorophore-conjugated antibodies were purchased from BD-Biosciences
and eBioscience. Stained cells were analyzed with a FACSCanto or LSRII
flow cytometer (BD Biosciences) and data were analyzed with FlowJo soft-576 Immunity 34, 566–578, April 22, 2011 ª2011 Elsevier Inc.ware (Treestar). Intracellular Foxp3 staining was performed with Foxp3 mouse
Treg cell staining kit (eBioscience). Flow cytometric analysis of pSTAT3 stain-
ing was performed according to manufacturer’s instructions by immediate
fixation with BD Phosflow Fix Buffer and Perm Buffer III (BD Biosciences).
Cytokine staining was performed after stimulation of splenocytes with PMA
(50 ng/ml) and ionomycin (500 ng/ml) for 4–6 hr in the presence of Golgi-
Plug (BD Biosciences). All antibodies used for flow cytometry staining were
purchased from eBioscience or BD Biosciences.
Single-cell suspensions from lymph nodes and spleen were generated by
mechanical disruption. CD4+CD25 naive T cells and CD4+CD25+ regulatory
T cells were purified with MACS isolation kits (Miltenyi Biotec, Germany)
according to the manufacturer’s protocol. Foxp3-YFP+ and Foxp3-YFP cells
were isolated by sorting on a FACS Aria cell sorter (BD Biosciences).
In Vitro Suppression Assays
For in vitro suppression assays, Treg cells and effector T cells were purified by
positive selection with CD4-specific beads (Invitrogen) followed by FACS sort-
ing. Antigen-presenting cells (APC) were prepared from wild-type C57BL/6J
splenocytes by T cell depletion with Thy1-specific MACS beads. Effector
T cells (2 3 104 cells/well) were cocultured with Treg cells at indicated ratios
in the presence of irradiated (2000 rad) APCs (13 105 cells/well) and CD3 anti-
body (1 mg/ml) in 96-well plates for 60 hr and pulsedwith 1 mCi 3H-thymidine for
additional 8–12 hr. Cell proliferation was measured with a scintillation counter.
The data are presented as mean cpm 3H-thymidine incorporation in triplicate
cultures and standard deviation.
Immunoblot Analysis
Whole-cell extracts from MACS (Miltenyi)-purified CD4+CD25 and CD4+
CD25+ T cells or FACS-sorted CD4+Foxp3 and CD4+Foxp3+ T cells were
prepared with RIPA lysis buffer and subjected to immunoblot analysis
with antibodies specific for STAT3 and pSTAT3 (Y705) (Cell Signaling
Technologies).
Quantitative PCR
Total RNA was extracted with TriZOL reagent (Invitrogen) from FACS-purified
IL-10R-sufficient and -deficient CD4+YFP+ Treg cells. cDNA was synthesized
with SuperscriptIII Reverse Transcriptase (Invitrogen), followed by real-time
PCR analysis (SYBR green; Applied Biosystems).
Histopathological Evaluation of Colitis
Samples of cecum and colon from 3–5 animals per group were fixed in 10%
neutral buffered formalin and routinely processed for hematoxylin and eosin
staining. Histological evaluation of colitis was performed as described previ-
ously (Burich et al., 2001). In brief, the cecum, proximal, middle, and distal
colon were scored by a pathologist on a 0–4 scale each for mucosal changes
(erosion, ulceration, and/or hyperplasia), inflammation, and extent of section
involvement. The total inflammation score (IBD score) was derived by
summing the scores from the individual segments and subsequently the
mean was derived for each experimental group.
Chromatin Immunoprecipitation
ChIP was performed as described previously (Zheng et al., 2007). CD4+CD25+
Treg cells from 6- to 8-month-old mice were isolated with Treg cell isolation kit
(Miltenyi Biotec). Antibody to STAT3 was used fromCell Signaling Technology.
Relative abundance of regions of interest in precipitated DNA was measured
by qPCR with Power SYBR-Green PCR master mix (Applied Biosystems).
Statistical Methods
Unless otherwise noted, statistical analysis was performed with the Student’s
t test on individual biological replicates in Prism (GraphPad).SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and can be found with this
article online at doi:10.1016/j.immuni.2011.03.018.
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